KLCM Advisors Inc. grew its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 75.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 173,793 shares of the biopharmaceutical company's stock after purchasing an additional 74,487 shares during the quarter. KLCM Advisors Inc.'s holdings in Pfizer were worth $5,004,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Front Street Capital Management Inc. raised its stake in shares of Pfizer by 4.3% during the 1st quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company's stock worth $268,000 after acquiring an additional 215 shares in the last quarter. Castleview Partners LLC raised its stake in shares of Pfizer by 2.4% during the 1st quarter. Castleview Partners LLC now owns 12,207 shares of the biopharmaceutical company's stock worth $498,000 after acquiring an additional 287 shares in the last quarter. United Bank raised its stake in shares of Pfizer by 0.6% during the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company's stock worth $2,416,000 after acquiring an additional 290 shares in the last quarter. Compton Capital Management Inc. RI raised its stake in shares of Pfizer by 0.5% during the 1st quarter. Compton Capital Management Inc. RI now owns 63,891 shares of the biopharmaceutical company's stock worth $3,308,000 after acquiring an additional 300 shares in the last quarter. Finally, GHP Investment Advisors Inc. raised its stake in shares of Pfizer by 2.4% during the 4th quarter. GHP Investment Advisors Inc. now owns 13,332 shares of the biopharmaceutical company's stock worth $683,000 after acquiring an additional 307 shares in the last quarter. Institutional investors own 68.36% of the company's stock.
Analyst Upgrades and Downgrades
Several analysts have weighed in on PFE shares. Guggenheim started coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a "buy" rating and a $36.00 target price on the stock. TD Cowen downgraded shares of Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Argus downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Friday, March 22nd. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $45.00 target price on shares of Pfizer in a research report on Monday. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $36.88.
Read Our Latest Analysis on PFE
Pfizer Stock Performance
Shares of PFE stock traded down $0.29 during trading hours on Wednesday, hitting $25.41. The company's stock had a trading volume of 43,790,104 shares, compared to its average volume of 42,573,164. The company has a 50 day moving average of $27.19 and a 200 day moving average of $28.76. Pfizer Inc. has a 12-month low of $25.26 and a 12-month high of $41.33. The stock has a market cap of $143.86 billion, a PE ratio of 70.57, a price-to-earnings-growth ratio of 1.18 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.
Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same period in the prior year, the firm posted $1.14 earnings per share. The firm's quarterly revenue was down 41.3% compared to the same quarter last year. On average, sell-side analysts forecast that Pfizer Inc. will post 2.22 EPS for the current fiscal year.
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Stories
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
